2025-05-22 06:01:36 pm | Source: reuters
India`s Sun Pharma posts quarterly profit rise on strong demand for rare disease drugs
Sun Pharmaceutical, India's largest drugmaker by revenue, reported a rise in adjusted quarterly profit on Thursday, driven by strong domestic demand for its drugs to treat rare diseases.
The Mumbai-based firm's consolidated profit before exceptional items and tax rose 24% to 36.16 billion rupees ($420.7 million) in the three months ended March 31.
Disclaimer:
The content of this article is for informational purposes only and should not be considered financial or
investment advice. Investments in financial markets are subject to market risks, and past performance is
not indicative of future results. Readers are strongly advised to consult a licensed financial expert or
advisor for tailored advice before making any investment decisions. The data and information presented
in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the
content of this article for any current or future financial references.
To Read Complete Disclaimer Click Here
Latest News
IRCTC delivers 58 crore meals a year, handles 18 lak...
Cabinet approves Rs 3,936 crore four-laning of Khaga...
India-US trade deal 99 pc finalised, remaining issue...
Jharkhand woman becomes 'Atmanirbhar' through poultr...
MCX's good?delivery norms for aluminium, copper and ...
Adani Foundation, Anushkaa Foundation launch initiat...
Buy Healthcare Global Enterprises Ltd for Target Rs....
Buy Global Health Ltd for the Target Rs. 1,460 by Ch...
India, South Africa agree to deepen cooperation in A...
Buy Fortis Healthcare Ltd for the Target Rs. 1,140 b...
